H.C. Wainwright Reiterates Buy Rating, $12 PT on CymaBay Therapeutic (CBAY) Apr 5, 2022 06:12AM
CymaBay Therapeutic (CBAY) PT Lowered to $12 at H.C. Wainwright Aug 3, 2021 06:54AM
UPDATE: H.C. Wainwright Upgrades CymaBay Therapeutic (CBAY) to Buy May 26, 2020 07:13AM
H.C. Wainwright Downgrades CymaBay Therapeutic (CBAY) to Neutral Nov 26, 2019 07:13AM
CymaBay Therapeutic (CBAY) PT Lowered to $12 at H.C. Wainwright Jun 12, 2019 12:23PM


Apr 13, 2018 07:50AM CymaBay Therapeutics (CBAY) Data Leak Shows Seladelpar More Competitive With Ocliva, PT To $21 - HCWainwright
Jan 24, 2018 07:43AM CymaBay Therapeutics (CBAY): 3 Catalsyts To Drive Value Creation, PT To $18 - HC Wainwright
Jul 17, 2017 09:49AM CymaBay Therapeutic (CBAY) PT Raised to $12 at H.C. Wainwright; 'Seladelpar's Phase 2 PBC Results More Robust Than Ocaliva'
Mar 30, 2017 07:28AM CymaBay Therapeutics (CBAY): Positive on the Appointment of Sujal Shah as Interim CEO - HC Wainwright
Mar 27, 2017 07:11AM CymaBay Therapeutic (CBAY) PT Raised to $7 at H.C. Wainwright; 'Transformational Year Ahead for Seladelpa'
Jan 30, 2017 07:05AM H.C. Wainwright Upgrades CymaBay Therapeutic (CBAY) to Buy
Jan 4, 2017 07:24AM CymaBay Therapeutics (CBAY): Raising PT After Deal Announcement - H.C. Wainwright